C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
eLife · 2025
DOI: 10.7554/elife.101830 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Toru Tanaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan. Hauptthemen laut MEDLINE: Atherosclerosis, Receptors, CCR4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KAKENHI, SENSHIN Medical Research Foundation, Ono Medical Research Foundation.
Abstract (Originalsprache)
Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Chemotherapy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan.
ORCID-Profile: Toru Tanaka, Naoto Sasaki, Aga Krisnanda, Sayo Horibe, Kazuhiko Matsuo, Takashi Nakayama, Yoshiyuki Rikitake
Förderung
- KAKENHI
- SENSHIN Medical Research Foundation
- Ono Medical Research Foundation
- Novartis Japan
- Pfizer Japan
- Astellas Pharma
Zitieren
APA
Tanaka, T., Sasaki, N., Krisnanda, A., Amin, H. Z., Ito, K., Horibe, S., Matsuo, K., Hirata, K. I., Nakayama, T., & Rikitake, Y. (2025). C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice. eLife. https://doi.org/10.7554/elife.101830
Vancouver
Tanaka T, Sasaki N, Krisnanda A, Amin HZ, Ito K, Horibe S, et al. C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice. eLife. 2025. doi:10.7554/elife.101830
BibTeX
@article{Tanaka2025,
author = {Tanaka, Toru and Sasaki, Naoto and Krisnanda, Aga and Amin, Hilman Zulkifli and Ito, Ken and Horibe, Sayo and Matsuo, Kazuhiko and Hirata, Ken-Ichi and Nakayama, Takashi and Rikitake, Yoshiyuki},
title = {C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.101830}
}
EUVIMED